JP Morgan Chase’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

JP Morgan Chase’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,682	Closed	-$61K	–	7837
2023 Q2	$61K	Sell	33,682 -19,903	-37%	-$36.4K	﹤0.01%	5665
2023 Q1	$71K	Buy	53,585 +33,719	+170%	+$55.1K	﹤0.01%	5575
2022 Q4	$34K	Buy	19,866 +1,253	+7%	+$1.59K	﹤0.01%	5735
2022 Q3	$34K	Buy	18,613 +3,463	+23%	+$10.3K	﹤0.01%	5666
2022 Q2	$47K	Buy	+15,150	New	+$92.5K	﹤0.01%	5680

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

JP Morgan Chase's PRDS Position: Q3 2023 in Review

JP Morgan Chase sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 33,682 shares — an estimated $61K sold.

JP Morgan Chase first reported a position in PRDS in Q2 2022 and held it in 5 quarters. The position peaked at $71K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

JP Morgan Chase reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 33,682 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $61K.
JP Morgan Chase first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
JP Morgan Chase's Pardes Biosciences, Inc. Common Stock position peaked at $71K in Q1 2023.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.